An appealing therapeutic target for AML is constitutively activated, mutant FLT3, which is
expressed in a subpopulation of AML patients and is generally a poor prognostic indicator in …

New studies indicate that the side population (SP) and cancer stem cells (CSC) drive and
maintain many types of human malignancies. SP and CSC appear to be highly resistant to …

Abstract Changes in the enzymatic activity of protein arginine methyltransferase (PRMT) 5
have been associated with cancer; however, the protein's role in acute myeloid leukemia …

FMS-like tyrosine kinase 3 (FLT3) is the most commonly mutated gene found in acute
myeloid leukemia (AML) patients and its activating mutations have been proven to be a …

Human myeloid leukemias provide models of maturation arrest and differentiation therapy of
cancer. The genetic lesions of leukemia result in a block of differentiation (maturation arrest) …

Dedicator of cytokinesis 2 (Dock2) can activate the downstream small G protein Rac and
regulate cytoskeletal reorganization. Dock2 is essential for critical physiological processes …

Cancers arise from stem cells in adult tissues and the cells that make up a cancer reflect the
same stem cell→ progeny→ differentiation progression observed in normal tissues. All adult …

The immunomodulatory effects of indoleamine 2, 3-dioxygenase (IDO) are ascribed to its
ability to catalyze breakdown of the essential amino acid l-tryptophan. We applied reverse …

Constitutively activated mutant FLT3 has emerged as a promising target for therapy for the
subpopulation of acute myeloid leukemia (AML) patients who harbor it. The small molecule …

The FMS-like tyrosine kinase-3 (FLT3) gene is the most commonly mutated gene in acute
myeloid leukemia (AML), and patients carrying internal tandem duplication (ITD) mutations …